| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A comprehensive approach to therapy of haematological malignancies in older patients
|
Cordoba, Raul
|
|
|
|
11 |
p. e840-e852
|
article
|
| 2 |
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial
|
Goldschmidt, Hartmut
|
|
|
|
11 |
p. e810-e821
|
article
|
| 3 |
A junior doctor on the other side of a bone marrow transplantation
|
Marjot, Jack
|
|
|
|
11 |
p. e793
|
article
|
| 4 |
Alternative donors: a match for matched sibling donors?
|
Inamoto, Yoshihiro
|
|
|
|
11 |
p. e545-e546
|
article
|
| 5 |
Am I a scientist?
|
Kerep, Ana Zelić
|
|
|
|
11 |
p. e878
|
article
|
| 6 |
An alternative to radiotherapy in consolidation of brain lymphoma
|
Schiff, David
|
|
2017
|
|
11 |
p. e498-e499
|
article
|
| 7 |
Analysis of an algorithm incorporating limited and whole-leg assessment of the deep venous system in symptomatic outpatients with suspected deep-vein thrombosis (PALLADIO): a prospective, multicentre, cohort study
|
Ageno, Walter
|
|
2015
|
|
11 |
p. e474-e480
nvt p.
|
article
|
| 8 |
Antibody-drug conjugates: when chemotherapy meets immuno-oncology
|
Mina, Roberto
|
|
|
|
11 |
p. e778-e779
|
article
|
| 9 |
Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis
|
Anagnostou, Theodora
|
|
|
|
11 |
p. e816-e826
|
article
|
| 10 |
A perspective on improving the R-CHOP regimen: from Mega-CHOP to ROBUST R-CHOP, the PHOENIX is yet to rise
|
Lue, Jennifer K
|
|
|
|
11 |
p. e838-e850
|
article
|
| 11 |
A rare blood disorder that created a watercolour storytelling movement
|
Keys, Kris
|
|
|
|
11 |
p. e790-e791
|
article
|
| 12 |
Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis
|
Bartelink, Imke H
|
|
2016
|
|
11 |
p. e526-e536
nvt p.
|
article
|
| 13 |
Authors' reply to comment Blood transfusion strategies in elderly patients
|
Simon, Geoff I
|
|
2017
|
|
11 |
p. e508
|
article
|
| 14 |
Authors' reply to comment What should be the endpoints of a symptomatic drug and its control?
|
Mesa, Ruben
|
|
2017
|
|
11 |
p. e508-e509
|
article
|
| 15 |
Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies
|
Thanarajasingam, Gita
|
|
2018
|
|
11 |
p. e563-e598
|
article
|
| 16 |
Biosimilars: when a negative study can be positive
|
Link, Brian K
|
|
2018
|
|
11 |
p. e500-e501
|
article
|
| 17 |
Blood transfusion in sub-Saharan Africa: walking a tightrope
|
Mpimbaza, Arthur
|
|
|
|
11 |
p. e774-e775
|
article
|
| 18 |
Blueprint for greater security of immunoglobulins for patients in Canada
|
Sher, Graham D
|
|
|
|
11 |
p. e804-e805
|
article
|
| 19 |
Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial
|
Cheson, Bruce D
|
|
|
|
11 |
p. e808-e815
|
article
|
| 20 |
Burning out—whose responsibility is it?
|
Kerep, Ana Zelić
|
|
|
|
11 |
p. e806
|
article
|
| 21 |
Can we not bleed?
|
The Lancet Haematology,
|
|
2016
|
|
11 |
p. e497-
1 p.
|
article
|
| 22 |
Cardiovascular disease after Hodgkin's lymphoma: a role for screening
|
Kupeli, Serhan
|
|
2015
|
|
11 |
p. e461-e462
nvt p.
|
article
|
| 23 |
Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials
|
Maraldo, Maja V
|
|
2015
|
|
11 |
p. e492-e502
nvt p.
|
article
|
| 24 |
Challenges facing women and girls with bleeding disorders
|
Doherty, Dearbhla
|
|
|
|
11 |
p. e875-e876
|
article
|
| 25 |
Changes in dynamics of excess mortality rates and net survival after diagnosis of follicular lymphoma or diffuse large B-cell lymphoma: comparison between European population-based data (EUROCARE-5)
|
Mounier, Morgane
|
|
2015
|
|
11 |
p. e481-e491
nvt p.
|
article
|
| 26 |
Changing the face of clinical trials
|
The Lancet Haematology,
|
|
|
|
11 |
p. e540
|
article
|
| 27 |
Changing views on adverse event reporting
|
Flores, Beatriz
|
|
2018
|
|
11 |
p. e506-e507
|
article
|
| 28 |
Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy
|
Joly, Bérangère S
|
|
2016
|
|
11 |
p. e537-e546
nvt p.
|
article
|
| 29 |
Chimeric antigen receptor T-cell therapy for acute lymphocytic leukaemia: where are we in 2020?
|
Laetsch, Theodore W
|
|
|
|
11 |
p. e778-e779
|
article
|
| 30 |
Clive Smith: pushing sporting boundaries
|
Smith, Clive
|
|
|
|
11 |
p. e877
|
article
|
| 31 |
Comparison of international guideline recommendations for the diagnosis of pulmonary embolism
|
Falster, Casper
|
|
|
|
11 |
p. e922-e935
|
article
|
| 32 |
Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia
|
Castillo, Jorge J
|
|
|
|
11 |
p. e827-e837
|
article
|
| 33 |
Correction to Lancet Haematol 2015; 2: e498
|
|
|
2015
|
|
11 |
p. e464-
1 p.
|
article
|
| 34 |
Correction to Lancet Haematol 2015; 2: e364
|
|
|
2015
|
|
11 |
p. e464-
1 p.
|
article
|
| 35 |
Correction to Lancet Haematol 2021; 8: e711–22
|
|
|
|
|
11 |
p. e789
|
article
|
| 36 |
Correction to Lancet Haematol 2021; 8: e67–79
|
|
|
|
|
11 |
p. e789
|
article
|
| 37 |
Correction to Lancet Haematol 2021; 8: e55–66
|
|
|
|
|
11 |
p. e789
|
article
|
| 38 |
Correction to Lancet Haematol 2020; 7: e456–68
|
|
|
|
|
11 |
p. e785
|
article
|
| 39 |
Correction to Lancet Haematol 2020; 7: e715–23
|
|
|
|
|
11 |
p. e785
|
article
|
| 40 |
Correction to Lancet Haematol 2019; 6: e489
|
|
|
|
|
11 |
p. e549
|
article
|
| 41 |
Correction to Lancet Haematol 2023; 10: e333–45
|
|
|
|
|
11 |
p. e874
|
article
|
| 42 |
Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study
|
Pabst, Thomas
|
|
|
|
11 |
p. e902-e912
|
article
|
| 43 |
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial
|
Lübbert, Michael
|
|
|
|
11 |
p. e879-e889
|
article
|
| 44 |
Decitabine versus intensive chemotherapy induction for older patients with acute myeloid leukaemia: a futile but successful trial
|
Montesinos, Pau
|
|
|
|
11 |
p. e866-e867
|
article
|
| 45 |
Defining low-risk high hyperdiploidy in patients with paediatric acute lymphoblastic leukaemia: a retrospective analysis of data from the UKALL97/99 and UKALL2003 clinical trials
|
Enshaei, Amir
|
|
|
|
11 |
p. e828-e839
|
article
|
| 46 |
Definition of functional iron deficiency and intravenous iron supplementation
|
Eisenga, Michele F
|
|
2016
|
|
11 |
p. e504-
1 p.
|
article
|
| 47 |
Definition of functional iron deficiency and intravenous iron supplementation – Author's reply
|
Khalafallah, Alhossain A
|
|
2016
|
|
11 |
p. e504-e505
nvt p.
|
article
|
| 48 |
Disparities in health care at stake in the 2020 US election
|
The Lancet Haematology,
|
|
|
|
11 |
p. e773
|
article
|
| 49 |
Dose-adjusted EPOCH-R plus venetoclax: a toxic bend in the road to improving R-CHOP?
|
Chamuleau, Martine E D
|
|
|
|
11 |
p. e781-e783
|
article
|
| 50 |
Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study
|
Eapen, Mary
|
|
|
|
11 |
p. e585-e596
|
article
|
| 51 |
Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study
|
Invernizzi, Rosangela
|
|
2015
|
|
11 |
p. e465-e473
nvt p.
|
article
|
| 52 |
Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial
|
Ogura, Michinori
|
|
2018
|
|
11 |
p. e543-e553
|
article
|
| 53 |
Elastic compression therapy to prevent post-thrombotic syndrome
|
Labropoulos, Nicos
|
|
2018
|
|
11 |
p. e494-e495
|
article
|
| 54 |
Embracing the complexity in cancer therapy
|
The Lancet Haematology,
|
|
2018
|
|
11 |
p. e493
|
article
|
| 55 |
Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study
|
Tiede, Andreas
|
|
|
|
11 |
p. e913-e921
|
article
|
| 56 |
Empowering patients with venous thromboembolism
|
The Lancet Haematology,
|
|
|
|
11 |
p. e865
|
article
|
| 57 |
European Congress on Thrombosis and Haemostasis 2019
|
del Pozo Martín, Yaiza
|
|
|
|
11 |
p. e550
|
article
|
| 58 |
Exercise training: a prescription for sickle-cell disease?
|
Kato, Gregory J
|
|
2018
|
|
11 |
p. e502-e503
|
article
|
| 59 |
Finally, what we have been waiting for: evidence that transfusion of RBCs at the extreme of the storage spectrum is safe
|
Gehrie, Eric A
|
|
2017
|
|
11 |
p. e504-e505
|
article
|
| 60 |
Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial
|
Popat, Uday R
|
|
2018
|
|
11 |
p. e532-e542
|
article
|
| 61 |
Gilbert's syndrome in haemopoietic cell transplantation
|
Arora, Mukta
|
|
2016
|
|
11 |
p. e500-e501
nvt p.
|
article
|
| 62 |
Haematopoietic stem-cell transplantation in older adults: geriatric assessment, donor considerations, and optimisation of care
|
Kennedy, Vanessa E
|
|
|
|
11 |
p. e853-e861
|
article
|
| 63 |
Have cancer, will travel
|
Downs, David
|
|
|
|
11 |
p. e792
|
article
|
| 64 |
Histological transformation and secondary malignancies in follicular lymphoma
|
Vitolo, Umberto
|
|
2018
|
|
11 |
p. e496-e497
|
article
|
| 65 |
Hodgkin lymphoma in pregnancy: good news for clinicians and women
|
Codacci-Pisanelli, Giovanni
|
|
|
|
11 |
p. e541-e542
|
article
|
| 66 |
Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial
|
Lonial, Sagar
|
|
|
|
11 |
p. e822-e832
|
article
|
| 67 |
Iberdomide with dexamethasone: a new backbone for myeloma treatment?
|
Rodriguez-Otero, Paula
|
|
|
|
11 |
p. e799-e801
|
article
|
| 68 |
Immunohaematological complications in patients with sickle cell disease after haemopoietic progenitor cell transplantation: a prospective, single-centre, observational study
|
Allen, Elizabeth S
|
|
2017
|
|
11 |
p. e553-e561
|
article
|
| 69 |
Immunotherapy for older patients with classic Hodgkin lymphoma
|
Connors, Joseph M
|
|
|
|
11 |
p. e776-e777
|
article
|
| 70 |
Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study
|
Kelly, Kevin R
|
|
|
|
11 |
p. e794-e807
|
article
|
| 71 |
Individually shortened duration versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome: a cost-effectiveness analysis
|
Amin, Elham E
|
|
2018
|
|
11 |
p. e512-e519
|
article
|
| 72 |
Inhibition of the CD47–SIRPα axis by TTI-621 to treat relapsed or refractory mycosis fungoides or Sézary syndrome
|
Stadler, Rudolf
|
|
|
|
11 |
p. e779-e781
|
article
|
| 73 |
Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study
|
Querfeld, Christiane
|
|
|
|
11 |
p. e808-e817
|
article
|
| 74 |
Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials
|
Stoffel, Nicole U
|
|
2017
|
|
11 |
p. e524-e533
|
article
|
| 75 |
Iron deficiency anaemia—an ongoing challenge
|
The Lancet Haematology,
|
|
|
|
11 |
p. e797
|
article
|
| 76 |
Isolated IgG4-related disease of the left maxillary antrum
|
Ramani, Pratibha
|
|
|
|
11 |
p. e862
|
article
|
| 77 |
Is pharmacokinetic guidance a must in busulfan regimens?
|
Kanda, Yoshinobu
|
|
2018
|
|
11 |
p. e498-e499
|
article
|
| 78 |
Join us at The Lancet Clinic
|
Kleinert, Sabine
|
|
2015
|
|
11 |
p. e463-
1 p.
|
article
|
| 79 |
Keeping the blood flowing during times of disaster
|
The Lancet Haematology,
|
|
2017
|
|
11 |
p. e497
|
article
|
| 80 |
Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Chanan-Khan, Asher A
|
|
2017
|
|
11 |
p. e534-e543
|
article
|
| 81 |
Life is a PAINting
|
Nazaire, Hertz
|
|
|
|
11 |
p. e787-e788
|
article
|
| 82 |
Limits of registry data to understand survival disparities in lymphoma
|
Olszewski, Adam J
|
|
2015
|
|
11 |
p. e459-e460
nvt p.
|
article
|
| 83 |
Living longer and better with haematological malignancies: a promise for older adults too?
|
Extermann, Martine
|
|
|
|
11 |
p. e784-e786
|
article
|
| 84 |
Maintenance lenalidomide could be most relevant after first-line therapy
|
Chang, Julie E
|
|
2017
|
|
11 |
p. e502-e503
|
article
|
| 85 |
Mantle cell lymphoma: minimal residual disease outcomes
|
Vose, Julie M
|
|
|
|
11 |
p. e775-e776
|
article
|
| 86 |
Maximising response depth is important in multiple myeloma
|
Chen, Xiaoyi
|
|
|
|
11 |
p. e798-e799
|
article
|
| 87 |
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial
|
Costa, Luciano J
|
|
|
|
11 |
p. e890-e901
|
article
|
| 88 |
Moderate-intensity endurance-exercise training in patients with sickle-cell disease without severe chronic complications (EXDRE): an open-label randomised controlled trial
|
Gellen, Barnabas
|
|
2018
|
|
11 |
p. e554-e562
|
article
|
| 89 |
Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group
|
Le Gouill, Steven
|
|
|
|
11 |
p. e798-e807
|
article
|
| 90 |
Mortality benefits of thromboprophylaxis
|
Eikelboom, John
|
|
|
|
11 |
p. e783
|
article
|
| 91 |
Mortality benefits of thromboprophylaxis – Authors' reply
|
Klemen, Nicholas D
|
|
|
|
11 |
p. e783-e784
|
article
|
| 92 |
Mortality outcomes after busulfan-containing conditioning treatment and haemopoietic cell transplantation in patients with Gilbert's syndrome: a retrospective cohort study
|
McDonald, George B
|
|
2016
|
|
11 |
p. e516-e525
nvt p.
|
article
|
| 93 |
MRD-guided treatment cessation in multiple myeloma
|
Derman, Benjamin A
|
|
|
|
11 |
p. e867-e868
|
article
|
| 94 |
Multi-organ graft-versus-host disease after nivolumab for relapsed Hodgkin lymphoma: the role of plasma exchange
|
Amerikanou, Rodothea
|
|
|
|
11 |
p. e862
|
article
|
| 95 |
Non-haematological grade 1 and 2 adverse events of frontline CPX-351 in patients with myelodysplastic syndromes
|
Sasaki, Koji
|
|
|
|
11 |
p. e872
|
article
|
| 96 |
Non-haematological grade 1 and 2 adverse events of frontline CPX-351 in patients with myelodysplastic syndromes – Authors' reply
|
Peterlin, Pierre
|
|
|
|
11 |
p. e872-e873
|
article
|
| 97 |
Obstetric and maternal outcomes in patients diagnosed with Hodgkin lymphoma during pregnancy: a multicentre, retrospective, cohort study
|
Maggen, Charlotte
|
|
|
|
11 |
p. e551-e561
|
article
|
| 98 |
Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial
|
Watanabe, Takashi
|
|
2018
|
|
11 |
p. e520-e531
|
article
|
| 99 |
Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis
|
Shouval, Roni
|
|
|
|
11 |
p. e573-e584
|
article
|
| 100 |
Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial
|
San-Miguel, Jesús F
|
|
2016
|
|
11 |
p. e506-e515
nvt p.
|
article
|
| 101 |
Panobinostat plus bortezomib and dexamethasone for relapsed myeloma
|
Pratt, Guy
|
|
2016
|
|
11 |
p. e498-e499
nvt p.
|
article
|
| 102 |
Place-of-care manufacturing of gene therapies
|
Adair, Jennifer E
|
|
|
|
11 |
p. e807-e808
|
article
|
| 103 |
Postnatal treatment for children with fetal and neonatal alloimmune thrombocytopenia: a multicentre, retrospective, cohort study
|
de Vos, Thijs W
|
|
|
|
11 |
p. e844-e853
|
article
|
| 104 |
Prioritising health equity alongside donation safety
|
Fingrut, Warren B
|
|
|
|
11 |
p. e802-e803
|
article
|
| 105 |
Prioritising health equity alongside donation safety – Authors' reply
|
Koh, Mickey B C
|
|
|
|
11 |
p. e803-e804
|
article
|
| 106 |
Rahul Bhargava: making bone marrow transplantation accessible in India
|
Wilkinson, Emma
|
|
|
|
11 |
p. e809
|
article
|
| 107 |
Rapidly loading emicizumab without immunosuppression in acquired haemophilia
|
Ragni, Margaret V
|
|
|
|
11 |
p. e870-e871
|
article
|
| 108 |
Real-world evidence in safety assessment of new treatments
|
Smedby, Karin E
|
|
2018
|
|
11 |
p. e510-e511
|
article
|
| 109 |
Red blood cell alloimmunisation in patients with sickle cell disease
|
Volt, Fernanda
|
|
2017
|
|
11 |
p. e506-e507
|
article
|
| 110 |
Red blood cell storage and in-hospital mortality: a secondary analysis of the INFORM randomised controlled trial
|
Cook, Richard J
|
|
2017
|
|
11 |
p. e544-e552
|
article
|
| 111 |
Redefining high hyperdiploid B-cell acute lymphoblastic leukaemia
|
Lafage-Pochitaloff, Marina
|
|
|
|
11 |
p. e783-e784
|
article
|
| 112 |
Role of autologous haematopoietic cell transplantation in the treatment of systemic light chain amyloidosis in the era of anti-CD38 monoclonal antibodies
|
Chakraborty, Rajshekhar
|
|
|
|
11 |
p. e936-e940
|
article
|
| 113 |
Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial
|
Lee, Jong Wook
|
|
|
|
11 |
p. e562-e572
|
article
|
| 114 |
Science over stigma: the need for evidence-based blood donation policies for men who have sex with men in the USA
|
Skelly, Ashwin N
|
|
|
|
11 |
p. e779-e782
|
article
|
| 115 |
Should unrelated haematopoietic progenitor cell donors be tested for CD36 in Japan?
|
Sato, Tomohiko
|
|
|
|
11 |
p. e802
|
article
|
| 116 |
Sophie Uyoga–reducing sickle cell stigma in Africa
|
Kirby, Tony
|
|
|
|
11 |
p. e786
|
article
|
| 117 |
Standardising busulfan dosage for children and young adults
|
Gorin, Norbert-Claude
|
|
2016
|
|
11 |
p. e502-e503
nvt p.
|
article
|
| 118 |
Stem cell stimulation continues to pay off in aplastic anaemia
|
Scheinberg, Phillip
|
|
|
|
11 |
p. e543-e544
|
article
|
| 119 |
Stem cell transplantation in sickle-cell disease
|
Sheth, Sujit
|
|
|
|
11 |
p. e547-e548
|
article
|
| 120 |
Targeting CD70 in acute myeloid leukaemia: an emerging therapeutic angle in combinatorial treatment
|
Fathi, Amir T
|
|
|
|
11 |
p. e868-e870
|
article
|
| 121 |
Telehealth and digital equity for older people
|
The Lancet Haematology,
|
|
|
|
11 |
p. e777
|
article
|
| 122 |
Thalidomide for hereditary haemorrhagic telangiectasia
|
Franchini, Massimo
|
|
2015
|
|
11 |
p. e457-e458
nvt p.
|
article
|
| 123 |
The cost of cure
|
Schmiegelow, Kjeld
|
|
2018
|
|
11 |
p. e504-e505
|
article
|
| 124 |
The effect of blood transfusion on outcomes among African children admitted to hospital with Plasmodium falciparum malaria: a prospective, multicentre observational study
|
Ackerman, Hans
|
|
|
|
11 |
p. e789-e797
|
article
|
| 125 |
The influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post-marketing research on the treatment of chronic myeloid leukaemia in the USA
|
Kantarjian, Hagop
|
|
|
|
11 |
p. e854-e861
|
article
|
| 126 |
The need to assess financial adverse events
|
Nastoupil, Loretta J
|
|
2018
|
|
11 |
p. e508-e509
|
article
|
| 127 |
The rising cost of orphan drugs
|
The Lancet Haematology,
|
|
2015
|
|
11 |
p. e456-
1 p.
|
article
|
| 128 |
Treatment of iron deficiency is getting trendy
|
Auerbach, Michael
|
|
2017
|
|
11 |
p. e500-e501
|
article
|
| 129 |
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial
|
Benjamin, Reuben
|
|
|
|
11 |
p. e833-e843
|
article
|
| 130 |
Under-recognition of measurement and management of serum ferritin among populations at high risk of iron deficiency
|
Sato, Tomohiko
|
|
|
|
11 |
p. e787
|
article
|
| 131 |
Under-recognition of measurement and management of serum ferritin among populations at high risk of iron deficiency – Authors' reply
|
Jefferds, Maria Elena
|
|
|
|
11 |
p. e787-e788
|
article
|
| 132 |
Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study
|
Rutherford, Sarah C
|
|
|
|
11 |
p. e818-e827
|
article
|
| 133 |
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial
|
Ferreri, Andrés J M
|
|
2017
|
|
11 |
p. e510-e523
|
article
|
Journal description